|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Thailand
Espicom Business Intelligence Ltd, Sep 2009, Pages: 46
This in-depth pharmaceutical market report is ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Executive Summary
Lax patent laws have brought widespread condemnation from industry players, and the compulsory licensing of drugs in 2006, 2007 and 2008 has exacerbated the situation. More compulsory licences are expected in the future.
The ’30 baht’ scheme first implemented in 2001, is designed to bring universal healthcare coverage to the Thai population in the long term. It was replaced with a new universal healthcare coverage scheme in November 2006.
The largest domestic drug manufacturer in Thailand is the Government Pharmaceutical Office (GPO) which has a near monopoly over the public hospital sector in the country. Public hospitals are legally obliged to purchase 80% of their drugs from the GPO.
The industry appears to be recovering with both imports and exports showing impressive growth in recent years.
In 2008, the Thai market for pharmaceuticals is estimated at US$1.7 billion, or US$25 per capita. It is expected that the pharmaceutical market will continue to expand at an annual rate of 4.7%. This will take the market to just under US$2.2 billion in 2013, equal to US$32 per capita.
Customers who bought this item also bought
The Pharmaceutical Market: Mexico
The Pharmaceutical Market: Philippines
The Pharmaceutical Market: Colombia
The Pharmaceutical Market: Canada
The Pharmaceutical Market: Ireland
The Pharmaceutical Market: China
The Pharmaceutical Market: Bulgaria
The Pharmaceutical Market: Morocco
The Pharmaceutical Market: Hong Kong
The Pharmaceutical Market: Switzerland
The Pharmaceutical Market: Singapore
The Pharmaceutical Market: Greece
|
|
|
|
